search
Back to results

Self-management of Low Molecular Weight Heparin Therapy

Primary Purpose

Thromboembolism

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
patient education
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Thromboembolism focused on measuring Heparin, Low-Molecular-Weight, compliance, drug safety, self-administration, ambulatory Care, Pharmaceutical Services

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients are recruited from orthopedic clinics, an emergency department and from community pharmacies with a prescription for a LMWH as an outpatient treatment.
  • self-application of the LMWH
  • german / english speaking

    -> clinical setting:

  • Dalteparin

    -> daily life setting:

  • all LMWH (ready-to-use syringes)
  • control group: self-application or application by another person (family member, medical person, etc.)

Exclusion Criteria:

- patient's home far away from study center

Sites / Locations

  • University Hospital of Basle, Switzerland
  • Kantonsspital Baselland, Switzerland

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

No Intervention

Experimental

No Intervention

Arm Label

clinical setting: intervention

clinical setting: standard care

daily life setting: intervention

daily life setting: standard care

Arm Description

Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital. Intervention: patient education

Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)

Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists. Intervention: patient education

Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)

Outcomes

Primary Outcome Measures

Drug Use Problems
During a home visit and at her/his individual injection time, each patient was monitored when self-administering an s.c. injection (directly observed therapy, DOT). Score minimum = -2.00; score maximum = +2.00 for the objective estimation of the application quality. Higher score values represent better outcomes.

Secondary Outcome Measures

Compliance
objectively determined by syringe count Therapy durations varied individually depending on the indication of the drug therapy (days to weeks).
Patient Satisfaction

Full Information

First Posted
November 18, 2008
Last Updated
November 5, 2014
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00794560
Brief Title
Self-management of Low Molecular Weight Heparin Therapy
Official Title
Self-management of Heparin Therapy - Drug Use Problems and Compliance With Self-injected Low Molecular Weight Heparin in Ambulatory Care
Study Type
Interventional

2. Study Status

Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
August 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
There is very little data available on compliance with self-injected low molecular weight heparins (LMWH), but what there is, definitely shows that compliance represents a significant problem. We therefore aim to a) record drug use problems of patients including compliance, b) develop a "SOP" for first instruction by a pharmacist and for subsequent pharmaceutical care and c) to compare intensive pharmaceutical care (intervention) vs. standard care (control) provided in the pharmacy to patients with a prescription for a LMWH as an outpatient treatment. Hypothesis: Intensive pharmaceutical care in ambulatory patients who self-inject low molecular weight heparins results in improved compliance, more safety and satisfaction as well as in fewer complications.
Detailed Description
Patient recruitment in community pharmacies enables the testing of the feasibility of the interventions under daily-practice conditions and facilitates the recruitment of a larger number of patients. Data collection: telephone interviews with structured questionnaires at the beginning and at the end of the therapy monitored self-injection in the study center or at patient's home (direct observation technique [DOT]) compliance measurement: answers from patient interviews, comparing number of used syringes vs. number of prescribed syringes (analogue "pill count"), measuring residual volume in recycled syringes recording of the fine motor skills by the adapted "Disabilities of the Arm, Shoulder and Hand" questionnaire (DASH questionnaire)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thromboembolism
Keywords
Heparin, Low-Molecular-Weight, compliance, drug safety, self-administration, ambulatory Care, Pharmaceutical Services

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
154 (Actual)

8. Arms, Groups, and Interventions

Arm Title
clinical setting: intervention
Arm Type
Experimental
Arm Description
Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital. Intervention: patient education
Arm Title
clinical setting: standard care
Arm Type
No Intervention
Arm Description
Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
Arm Title
daily life setting: intervention
Arm Type
Experimental
Arm Description
Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists. Intervention: patient education
Arm Title
daily life setting: standard care
Arm Type
No Intervention
Arm Description
Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
Intervention Type
Behavioral
Intervention Name(s)
patient education
Intervention Description
Possible, individualized interventions: Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes) Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom First self-injection under control of a specially trained pharmacist
Primary Outcome Measure Information:
Title
Drug Use Problems
Description
During a home visit and at her/his individual injection time, each patient was monitored when self-administering an s.c. injection (directly observed therapy, DOT). Score minimum = -2.00; score maximum = +2.00 for the objective estimation of the application quality. Higher score values represent better outcomes.
Time Frame
during the individual drug therapy, an average of 18 days
Secondary Outcome Measure Information:
Title
Compliance
Description
objectively determined by syringe count Therapy durations varied individually depending on the indication of the drug therapy (days to weeks).
Time Frame
at the end of the individual drug therapy, an average of 18 days
Title
Patient Satisfaction
Time Frame
at the end of the individual drug therapy, an average of 18 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients are recruited from orthopedic clinics, an emergency department and from community pharmacies with a prescription for a LMWH as an outpatient treatment. self-application of the LMWH german / english speaking -> clinical setting: Dalteparin -> daily life setting: all LMWH (ready-to-use syringes) control group: self-application or application by another person (family member, medical person, etc.) Exclusion Criteria: - patient's home far away from study center
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kurt E. Hersberger, Prof. PhD
Organizational Affiliation
Pharmaceutical Care Research Group, University of Basle, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Basle, Switzerland
City
Basle
ZIP/Postal Code
CH-4031
Country
Switzerland
Facility Name
Kantonsspital Baselland, Switzerland
City
Bruderholz
ZIP/Postal Code
CH-4101
Country
Switzerland

12. IPD Sharing Statement

Citations:
Citation
Mengiardi S, Tsakiris DA, Molnar V, et al. Impact of Pharmaceutical Care on Self-Administration of Outpatient Low-Molecular-Weight Heparin Therapy. Pharmacology & Pharmacy 5: 372-385, 2014
Results Reference
result

Learn more about this trial

Self-management of Low Molecular Weight Heparin Therapy

We'll reach out to this number within 24 hrs